These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 7826834)

  • 1. Preliminary study of the efficacy of xamoterol in bradycardia-tachycardia syndrome.
    Mizutani N; Kobayashi T; Watanabe T
    Br J Clin Pharmacol; 1994 Sep; 38(3):285-7. PubMed ID: 7826834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xamoterol in sinus node disease.
    Avery PG; Small J; Shaw DB
    Int J Cardiol; 1993 Jun; 40(1):45-9. PubMed ID: 8349365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo controlled trial of xamoterol versus digoxin in chronic atrial fibrillation.
    Ang EL; Chan WL; Cleland JG; Moore D; Krikler SJ; Alexander ND; Oakley CM
    Br Heart J; 1990 Oct; 64(4):256-60. PubMed ID: 1977430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation.
    Lundström T; Moor E; Rydén L
    Am Heart J; 1992 Oct; 124(4):917-23. PubMed ID: 1356311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xamoterol improves the control of chronic atrial fibrillation in elderly patients.
    Lawson-Matthew PJ; McLean KA; Dent M; Austin CA; Channer KS
    Age Ageing; 1995 Jul; 24(4):321-5. PubMed ID: 7484490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketotifen and cardiovascular effects of xamoterol following single and chronic dosing in healthy volunteers.
    Schäfers RF; Karl I; Mennicke K; Daul AE; Philipp T; Brodde OE
    Br J Clin Pharmacol; 1999 Jan; 47(1):59-66. PubMed ID: 10073741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [How to select newly-developed oral inotropic agents: an evaluation based on their effects on heart rate and arrhythmias].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    J Cardiol; 1990; 20(3):755-65. PubMed ID: 2151866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.
    Lancet; 1990 Jul; 336(8706):1-6. PubMed ID: 1694945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of the partial beta 1-agonist xamoterol on heart rate and ventricular arrhythmias in patients with mild to moderate heart failure.
    Virk SJ; Anfilogoff NH; Lawson N; Qiang F; Murray RG; Littler WA; Davies MK
    Eur Heart J; 1990 Oct; 11(10):876-84. PubMed ID: 1979946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of pharmacodynamic interactions between acute dose flosequinan and xamoterol. A pilot study in healthy subjects.
    Ng HW; Walley TJ; Tsao Y; Breckenridge AM
    Eur J Clin Pharmacol; 1994; 46(4):361-5. PubMed ID: 7957523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of beta receptor antagonists in patients with clinical evidence of heart failure after myocardial infarction: double blind comparison of metoprolol and xamoterol.
    Persson H; Rythe'n-Alder E; Melcher A; Erhardt L
    Br Heart J; 1995 Aug; 74(2):140-8. PubMed ID: 7546992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiologic noninvasives parameters in patients with sick sinus syndrome and syncopal attacks.
    Nicolin M; Drăgulescu SI; Petrescu LP
    Rom J Intern Med; 1994; 32(2):143-52. PubMed ID: 7920329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predominant beta-adrenoceptor blocking effect of xamoterol averaged over the day in patients with mild to moderate heart failure: insight into the mechanism of its long-term clinical efficacy.
    Ozaki H; Sato H; Hori M; Matsuyama T; Imai K; Yokoyama H; Kitabatake A; Inoue M; Kamada T
    Eur J Clin Pharmacol; 1992; 43(5):455-61. PubMed ID: 1362383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cardiovascular effects of xamoterol, a beta 1-adrenoceptor partial agonist, in healthy volunteers at rest.
    Hashimoto T; Shiina A; Toyo-Oka T; Hosoda S; Kondo K
    Br J Clin Pharmacol; 1986 Mar; 21(3):259-65. PubMed ID: 2421751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acute electrophysiologic and echocardiographic changes induced by xamoterol in chronic chagasic patients with sinus node dysfunction].
    Ladeira R; Tosta C; Pimenta J
    Arq Bras Cardiol; 1993 Sep; 61(3):165-9. PubMed ID: 8110046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation.
    Cappato R; Castelvecchio S; Ricci C; Bianco E; Vitali-Serdoz L; Gnecchi-Ruscone T; Pittalis M; De Ambroggi L; Baruscotti M; Gaeta M; Furlanello F; Di Francesco D; Lupo PP
    J Am Coll Cardiol; 2012 Oct; 60(15):1323-9. PubMed ID: 22981555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects and dose-response relationship of xamoterol in patients with ischaemic heart disease.
    Molajo AO; Bennett DH; Marlow HF; Snow HM; Bastain W
    Br J Clin Pharmacol; 1987 Sep; 24(3):373-9. PubMed ID: 2889460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and the effects of xamoterol in idiopathic dilated cardiomyopathy.
    Watanabe K; Hirokawa Y; Suzuki K; Masani F; Otsuka H; Izumi T; Shibata A
    J Cardiol; 1992; 22(2-3):417-25. PubMed ID: 1339800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ivabradine in four patients with inappropriate sinus tachycardia: a three month-long experience based on electrocardiographic, Holter monitoring, exercise tolerance and quality of life assessments.
    Kaplinsky E; Comes FP; Urondo LS; Ayma FP
    Cardiol J; 2010; 17(2):166-71. PubMed ID: 20544616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral xamoterol in patients with sinoatrial disease.
    Tseu FL; Morley CA; Mackintosh AF
    Br Heart J; 1986 Nov; 56(5):469-72. PubMed ID: 2878676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.